logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12636290 B1

PDFFull Text
Date of Patent:
May. 26, 2026

Filed:

Dec. 18, 2019

Bet inhibitors for modulating dux4 expression in fshd

Applicant:

Saint Louis University, St. Louis, MO (US);

Inventors:

Marvin J. Meyers, Wentzville, MO (US);

Francis M. Sverdrup, Lake Saint Louis, MO (US);

Timothy Caldwell, Lawrence, KS (US);

Jonathan Oliva, Manchester, MO (US);

Assignee:

Saint Louis University, St. Louis, MO (US);

Attorney:

pH IP Law

Primary Examiner:

Kortney L Klinkel

Assistant Examiner:

Richard Grant Peckham

Int. Cl.
CPC ...
A61K 31/551 (2006.01); A61K 31/137 (2006.01); A61K 31/4353 (2006.01); A61K 31/44 (2006.01); A61K 31/444 (2006.01); A61K 31/4704 (2006.01); A61K 31/4706 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/5513 (2006.01); A61K 31/5517 (2006.01); A61P 21/00 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/551 (2013.01); A61K 31/137 (2013.01); A61K 31/4353 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4704 (2013.01); A61K 31/4706 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/5513 (2013.01); A61K 31/5517 (2013.01); A61P 21/00 (2018.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01);
Abstract

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Find Patent Forward Citations

Loading…